Fecal Occult Blood Test, Is it still worth for Colorectal Cancer Screening?

Author:

Esmer Ahmet Cem1,Yeğen Şevket Cumhur1

Affiliation:

1. Department of General Surgery, Marmara University Pendik Training and Research Hsopital, Istanbul, Turkey

Abstract

<b>Introduction:</b> One of the most critical factors determining survival in cases of colorectal cancer is diagnosis and treatment at an early stage. Diagnosis at an early stage is possible with screening programs carried out within preventive health services.</br></br> <b>Aim:</b> : In this study, we aimed to compare the results of patients who underwent colonoscopy because of a positive fecal occult blood test (FOBT) with those over 50 years of age who underwent colonoscopy due to other complaints and to reveal whether an FOBT test is still essential for screening programs.</br></br> <b>Methods:</b> This study included patients who underwent colonoscopy between January 2016 and December 2021. The patients were analyzed in two groups, according to the reasons for colonoscopy: Group I (FOBT-positive) and Group II (other reasons).</br></br> <b>Results:</b> A total of 3393 patients were included in the study. They were divided into two groups for evaluation: those who underwent colonoscopy after a positive FOBT (Group I) and patients over 50 years of age who underwent colonoscopy for other reasons (Group II). When the colonoscopy findings were compared between the groups, inflammatory bowel disease (p = 0.03) was more prevalent in Group I, while normal colonoscopy (p = 0.03) was found to be more common in Group II. Polyps, malignancy, diverticulosis, and perianal diseases appeared to be statistically similar between the groups.</br></br> <b>Conclusion:</b> FOBT can still be used in colorectal screening because it is inexpensive and widely available, is more acceptable to patients due to its non-invasiveness, and can be applied outside of clinical settings.

Publisher

Index Copernicus

Subject

General Medicine,Surgery

Reference19 articles.

1. Sung H., Ferlay J., Siegel R.L. et al.: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185countries. CA Cancer J Clin., 2021; 71(3): 209–249. DOI: 10.3322/caac.21660

2. Schreuders E.H., Ruco A., Rabeneck L. et al.: Colorectal cancer screening:a global overview of existing programmes. Gut., 2015; 64(10): 1637–1649.DOI: 10.1136/gutjnl-2014-309086. Epub 2015 Jun 3. PMID: 26041752.

3. TC SB Halk Sağlığı Genel Müdürlüğü Kolorektal Kanser Tarama ProgramıUlusal Standartları. (TC MoH General Directorate of Public Health Colorectal Cancer Screening Program National Standards) https://hsgm.saglik.gov.tr/depo/birimler/kanser-db/yayinlar/raporlar/kolorektal.pdf (19.05.2022).

4. Türk Kolon ve Rektum Cerrahisi Derneği Kolorektal Kanserde tarama vetakip (Turkish Colon and Rectal Surgery Society screening and follow-uprecommendations in Colorectal Cancer) https://www.tkrcd.org.tr/kolorektal-kanserde-tarama-ve-takip (19.05.2022).

5. Paimela H., Malila N., Palva T. et al.: Early detection of colorectal cancer withfaecal occult blood test screening. Br J Surg., 2010; 97(10): 1567–1571. DOI:10.1002/bjs.7150. PMID: 20603855.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3